Market Size & Trends
The global cell and gene therapy bioanalytical testing services market size was valued at USD 541.5 million in 2024 and is expected to grow at a CAGR of 7.40% from 2025 to 2030. The growing need for cell and gene therapies to treat serious and rare diseases is a major reason why more people are looking for cell and gene therapy bioanalytical testing services.
Key Highlights
- North America dominated the cell and gene therapy bioanalytical testing services market and accounted for the largest revenue share (41.57%) in 2024.
- The cell and gene therapy bioanalytical testing services market in the U.S. is anticipated to witness significant growth over the forecast period.
- By test type, the bioavailability and bioequivalence studies dominate, with a market share of 35.44% in 2024, and they are also expected to witness the fastest growth over the forecast period.
- By stage of development by product type, the non-clinical segment dominated the market in 2024.
- By product type, the cell therapy segment dominated the product segment in 2024.
Moreover, rising research activities coupled with the rising funding for clinical research in cell & gene therapy and the significant rise in the number of cell and gene therapy drug candidates undergoing clinical trials present a key driver for the cell & gene therapy bioanalytical testing services industry.
Cell & gene therapies have been widely used in cancer, autoimmune diseases, rare diseases, and others. CAR-T therapies are one of the most advanced, capable of detecting and killing cancer cells more effectively. CAR-T cell therapies represent the majority of gene-modified cell therapies, with approximately 90% currently undergoing preclinical testing for oncology-related diseases. Hence, the aforementioned factors are anticipated to boost market growth
The development of cell & gene therapy is expensive. Therapy costs range from around USD 400,000 to over USD 2 million per dose. The high cost of the treatment is due to the high cost involved in drug development and manufacturing. There is a growing need to reduce the in-house costs of manufacturers in developing cell & gene therapy; therefore, outsourcing clinical research services such as bioanalytical testing and drug manufacturing to contract developers reduces the overall cost of cell & gene therapy drugs. This scenario is expected to support market growth.
A significant number of drugs related to cell and gene therapy are currently undergoing clinical studies. For instance, in a remarkable development, a six-month-old patient named KJ received a custom CRISPR-based gene editing therapy aimed at correcting a mutation responsible for CPS1 deficiency, a rare and potentially fatal liver condition. This innovative treatment, created by scientists at the Children's Hospital of Philadelphia and the University of Pennsylvania, is the first in vivo gene editing therapy explicitly designed for an individual patient. Moreover, according to a leading publisher, Pharma Intelligence, Asia Pacific has witnessed a boom in the cell and gene therapy research industry over the past few years. The majority of cell & gene therapy-related pipelines are in Asia Pacific owing to high awareness about the potential of cell & gene therapy in treating life-threatening diseases. We expect a significant number of cell & gene therapy trials to support market growth.
Report Coverage & Deliverables
The PDF report & online dashboard will help you understand
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Opportunity Analysis
The cell and gene therapy (CGT) sector offers significant opportunities for bioanalytical testing service providers, fueled by a growing pipeline of complex biologics. As regulatory agencies improve their rules about measuring effectiveness, vector copy number, immune response, and how products spread in the body, the need for specialized bioanalytical skills is growing. Additionally, there are great opportunities to create reliable tests for viral vectors like AAV and lentivirus, CAR-T cells, and gene-edited products. Service providers with expertise in qPCR, ddPCR, flow cytometry, and ELISA-based immunoassays are strategically placed to support studies from preclinical phases to post-market evaluations. The need for companion diagnostics and ongoing patient follow-up testing further accelerates this growth. Many emerging CGT sponsors may not have in-house testing capabilities and are turning to bioanalytical contract research organizations (CROs) for support. Moreover, the key differentiators will include the establishment of GLP-compliant laboratories, expedited turnaround times, and the provision of regulatory support services. Overall, because CGT products are complex and have strict rules, bioanalytical testing is very important and valuable for specialized CROs and labs around the world.
Funding/Investment Analysis
Investment in cell therapies has surged due to their immense market potential, driven by successful clinical trials and regulatory approvals. Technological advancements like CRISPR-Cas9 have enhanced the efficacy and safety of cell-based treatments, attracting investors seeking high-growth opportunities in the biotechnology sector. Strategic partnerships and regulatory support further accelerate development timelines and mitigate risks. Global investment trends show a diversification of portfolios, with the U.S., Europe, and Asia all witnessing increased funding in this space. Despite promising prospects, challenges such as manufacturing scalability and reimbursement hurdles make it imperative to employ cautious investment strategies. On the other hand, start-ups play a crucial role in driving innovation and expanding the landscape of cell therapies. These companies often pioneer novel approaches and technologies, capitalizing on scientific breakthroughs to develop cutting-edge therapies for various diseases.
Impact of U.S. Tariffs on the Global Cell & Gene Therapy Bioanalytical Testing Services Market
U.S. tariffs on imported scientific equipment, reagents, and laboratory supplies have considerably impacted the global cell & gene therapy bioanalytical testing services industry. These tariffs have increased the operational costs for cell and gene therapy and bioanalytical testing services. The increased costs are primarily due to the tariffs directly affecting the prices of high-precision instruments, chromatographic columns, reagents, and bioanalytical kits, many of which are sourced from international suppliers, including those in China and the European Union. Thus, due to these rising expenses, biotech companies, especially small and medium-sized enterprises, face financial strain that could lead to reduced research and development budgets. This economic pressure may ultimately delay innovation and the rollout of new therapies. To address these challenges, some companies seek to relocate clinical trials to regions with lower operating expenses, such as Europe, which is known for its established infrastructure and favorable regulatory conditions.
Moreover, major pharmaceutical companies like Roche have declared substantial investments in U.S. manufacturing. Roche intends to allocate USD 50 billion over the next five years to construct new facilities, including a manufacturing plant for gene therapy in Pennsylvania, to decrease dependency on imports & sidestep tariff-related expenses. Furthermore, U.S. tariffs have disrupted supply chains, raised costs, and prompted strategic adjustments in the CGT bioanalytical testing services sector, affecting global business operations and investment decisions.
Technological Advancements
Technological innovations are changing bioanalytical testing services for cell and gene therapies, making them more accurate, easier to scale, and better at meeting regulatory standards. Improvements in droplet digital PCR (ddPCR) and next-generation sequencing (NGS) have greatly enhanced the ability to accurately measure vector copy numbers, study how the treatment spreads in the body, and check for unintended effects. High-throughput flow cytometry and single-cell analysis allow for detailed immune profiling and testing of cell identities in CAR-T and TCR therapies. Furthermore, automation and robotics are increasing the throughput of assays while minimizing variability in potency and immunogenicity testing. AI-driven analytics and bioinformatics tools enhance the interpretation of extensive and complex datasets, delivering real-time insights throughout clinical phases. The use of lab-on-a-chip and microfluidics technologies is making it easier to quickly test patients during CGT trials. These new technologies are likely to meet the growing regulatory requirements and the need for larger-scale CGT programs, giving contract research organizations (CROs) an edge in helping biotech and biopharma companies worldwide.
Pricing Model Analysis
In cell and gene therapy bioanalytical testing services, pricing structures adapt to reflect the complexities and risks associated with advanced treatments. A milestone-based pricing approach is commonly implemented and utilized by around 60% of CGT-focused CROs. This model links payment to project milestones, including assay development, validation, and clinical trial support. It helps reduce financial risk for sponsors and aligns payment with the project's progress. In addition, value-based pricing is becoming increasingly popular for critical assays, particularly when testing significantly affects regulatory approvals or patient outcomes. This model ties compensation to performance metrics like assay accuracy, turnaround time, or regulatory acceptance, fostering innovation and accountability. A fixed-fee structure is often preferred for standardized assays or repeated testing in later-stage trials. This model provides cost predictability and is straightforward to budget, although it can be inflexible regarding changes in scope. Furthermore, a subscription or retainer model emerges among early-stage CGT developers, allowing consistent access to a range of testing services for a fixed monthly fee, ideal for ongoing, adaptable projects.
Market Concentration & Characteristics
The market is characterized by a moderate-to-high level of innovation, including the rapid advancements in cell and gene therapy technologies, like the development of biosimilars, combination products, and other innovative medicines, which define the market. Industry participants are investing in innovative techniques and technologies to meet the global demand for the market.
The market is also characterized by the leading players with moderate levels of merger and acquisition (M&A) activity and product launches. Market players like Syneos Health, Labcorp, Thermo Fischer Scientific Inc., Bayer, and others are involved in research expenditures, new product launches, and merger and acquisition activities. For instance, In March 2025, Labcorp announced an agreement to acquire assets of BioReference Health, a subsidiary of OPKO Health. The acquisition focuses on BioReference's laboratory testing businesses, particularly in oncology and related clinical testing services across the U.S., aiming to strengthen Labcorp's presence in specialized bioanalytical testing. Such strategic activities as M&A, expansions, partnerships, and collaborations increase companies' competitiveness, expand their geographic reach, and help them enter new territories.
Regulatory control and increasing awareness regarding the bioanalytical testing of CGT are paramount to ensuring the safety, efficacy, and quality of these advanced treatments. Regulatory agencies such as the U.S. FDA and EMA have established stringent guidelines to govern the development and approval of cell and gene therapies, mandating thorough bioanalytical testing throughout the product lifecycle. This heightened regulatory scrutiny points to the urgent need for comprehensive testing to mitigate risks and ensure patient safety. Global regulatory standards are being standardized to accelerate the approval process for cell and gene therapy bioanalytical testing services.
The market is characterized by a moderate level of service expansion with the help of specialized expertise and advanced equipment used for accurate testing. The expansion of bioanalytical testing facilities for CGT reflects a growing recognition of the importance of rigorous testing in ensuring the safety and efficacy of these advanced therapies. New novel methods might act as a key factor for expansion. However, widespread adoption of these technologies would depend on regulatory approval and acceptance by industry. Such advances in the near future might keep service expansion at a moderate level.
The regional expansion is crucial for any manufacturer in the market space. Bioanalytical testing facilities are expanding to accommodate this demand, equipped with state-of-the-art technology and expertise to characterize these complex therapies accurately.
Test Type Insights
The bioavailability and bioequivalence studies dominate, with a market share of 35.44% in 2024, and they are also expected to witness the fastest growth over the forecast period. Bioavailability & bioequivalence studies are conducted for drug development. All stages of the trial use it to test the drug's safety and efficacy. Drugs with low bioavailability do not provide therapeutic action. Bioequivalence studies are used to compare the pharmacokinetic profile of a generic drug; a significant number of biosimilar versions of cell and gene drugs entering the pipeline support the demand for bioequivalence studies on the market.
The pharmacokinetic segment is expected to grow at a considerable CAGR over the forecast period. Pharmacokinetics (PK) studies determine the extent of absorption, distribution, metabolism, and excretion of drugs in the body. This type of study is essential during drug development. These studies help identify the drug's safety and efficacy in the body. In February 2024, the company Optibrium launched Semeta software, which uses AI to predict drug metabolism and enhance the clinical success of the drugs being investigated. This tool is helpful for Drug Metabolism and Pharmacokinetics (DMPK) scientists. So, the growing number of cell and gene products is driving the need for pharmacokinetics services, which helps this area grow.
Stage of Development by Product Type Insights
The non-clinical segment dominated the market in 2024. The stage of development segment has been further classified based on the product type, which includes gene therapy, gene-modified cell therapy, and cell therapy. The large cell and gene therapeutics pipeline in the nonclinical developmental stage further demonstrates the segment's growth potential. For instance, in February 2024, data published by Cell & Gene showed that 10% of all U.S. FDA-registered novel drug pipelines were cell & gene therapy related. Furthermore, a 2023 report from the American Society of Gene and Cell Therapy highlighted a significant expansion in the gene, cell, and RNA therapy pipeline, including various therapeutic interventions in different developmental stages. The high demand among researchers for therapy in the clinical stage further supports the demand for non-clinical bioanalytical testing services, thus promoting the segment's market growth.
The clinical segment is expected to grow at the second-fastest CAGR over the analysis timeframe. Key bioanalytical services provided in the clinical stage include assay-based studies, choosing reagents, monitoring stability and quantification, pharmacokinetics studies, and validating methods. Across all the clinical phases, bioanalytical testing is conducted to analyze the safety and efficacy of the drug. In the clinical phase, human urine, plasma, and serum samples are used for bioanalytical testing. This type of analysis in humans is essential for drug approval from the regulatory authority. Moreover, it also gives the researchers better insights into drug safety. These factors support the demand for bioanalytical testing services at the clinical stage. For instance, as per the American Society of Cell & Gene Therapy, there was a significant increase in Phase I clinical trials in gene therapy from 270 therapies in 2023 to 301 in 2024. Such factors are anticipated to drive the segment’s growth.
Product Type Insights
The cell therapy segment dominated the product segment in 2024. Cell therapy is the transplantation of human cells to repair or replace damaged tissue or cells. Cell therapies have enormous potential in treating autoimmune diseases, cancers, urinary problems, infectious diseases, neurological disorders, and other diseases. Globally, numerous clinical research studies have focused on cell therapy. According to the American Society of Cell & Gene Therapy, over 885 studies focused solely on cell therapy as of April 2024. Furthermore, we expect collaborative initiatives among biotechnology enterprises, pharmaceutical companies, and CDMOs to propel the market and optimize development efforts. For instance, in January 2024, Israel-based biotech company Pluri announced the launch of a new business segment, PluriCDMO, aiming to provide comprehensive cell and gene therapy bioanalytical testing services.
The gene-modified cell therapy segment is expected to register the fastest growth during the forecast period. Gene-modified cell therapy includes CAR-NK cell therapy, CAR T-cell therapies, TCR-T cell therapy, and others. CAR T-cell therapies have gained much traction in the past five years. CAR T-cell therapies are considered very effective against some types of cancer; when other treatments are not working, CAR T therapy has shown remarkable results in treating Leukemia and Lymphoma. CAR-NK cell therapy is considered a promising cancer therapy and safer than CAR T-cell therapies for treating cancer. We expect these factors to fuel the demand for clinical research on gene-modified cell therapy.
Indication Insight
The oncology segment dominated the market and accounted for the largest revenue share in 2024. This is attributable to the high burden of cancer worldwide, and the growing demand for an effective treatment option for cancer is one of the major reasons for the segment's market growth. The demand for outsourced development services in oncology has increased due to the emergence of innovative cell and gene therapies designed for cancer treatment. For instance, a report published by the American Cancer Society in December 2024 estimated 2,001,140 new cancer cases with 611,720 related deaths in the U.S. As the incidence of cancer continues to rise globally, there is an increasing demand for innovative and effective treatment options.
The rare diseases segment is expected to register the fastest CAGR during the forecast period. This is attributable to the remarkable progress in cell and gene therapy, including targeted and personalized treatment modalities for previously incurable conditions. CDMOs dedicated to this sector have been pivotal in translating scientific discoveries into viable therapeutic solutions. Their services include process development, manufacturing scale-up, quality assurance, and adherence to regulatory compliance. For instance, in February 2024, Andelyn Biosciences, Inc., a CDMO specializing in cell and gene therapy, was chosen as the manufacturing partner for AAV therapies using its suspension platform by the Foundation for the National Institutes of Health (FNIH). This selection was part of collaborative efforts to accelerate the medicinal partnership, the Bespoke Gene Therapy Consortium (BGTC).
Regional Insight
North America dominated the cell and gene therapy bioanalytical testing services market and accounted for the largest revenue share of 41.57% in 2024. This can be attributed to numerous cell and gene therapy clinical trials across the U.S. The growing need for personalized medicine, rising investment in cell and gene therapy research and development (R&D), and the increasing incidence of genetic and chronic diseases are among the factors contributing to market growth in the region. Investments in cell and gene therapy R&D have significantly increased in the region. In addition, the presence of major players such as IQVIA, Laboratory Corporation of America Holdings, Charles River Laboratories, and a few others in the U.S., providing quality services in the region, has further boosted the revenue shares of the region in the market.
U.S. Cell And Gene Therapy Bioanalytical Testing Services Market Trends
The cell and gene therapy bioanalytical testing services market in the U.S. is anticipated to witness significant growth over the forecast period, as several pharmaceutical and biotechnology companies operate in this country. Increasing R&D investments and growing partnerships and collaborations among academic institutions, biopharmaceutical corporations, and CROs are contributing to the growth of cell and gene therapy bioanalytical testing services. These partnerships promote innovation and market growth by facilitating information sharing, resource access, and common infrastructure for bioanalytical testing. We anticipate that these factors will propel the growth of the market.
The Canada cell and gene therapy bioanalytical testing services market is growing due to increasing investments, collaborations, and other strategic initiatives undertaken by global biopharmaceutical companies conducting research in healthcare illness domains. We project Canada's well-established biotechnology industry to drive the market for cell and gene therapy bioanalytical testing services in this country.
Europe Cell And Gene Therapy Bioanalytical Testing Services Market Trends
Europe's cell and gene therapy bioanalytical testing services market is driven by regulatory agencies, such as the European Medicines Agency (EMA), which offer possibilities for rapid approval and limited marketing authorization for novel therapies. This favorable regulatory environment promotes investment and innovation in cell & gene therapies. The EMA, the medical regulatory body for the European Union, has been a global leader in evaluating advanced therapy medicinal products, a class of novel biological products that includes gene therapy.
Over the forecast period, we anticipate significant growth in the UK's cell and gene therapy bioanalytical testing services market. Stevenage Bioscience Catalyst and The Cell and Gene Therapy Catapult (CGT Catapult), two independent institutes with a focus on therapeutics and cutting-edge expertise in cell and gene technologies, have contributed to this growth. For instance, CGT Catapult is an independent innovation and technology organization dedicated to making a difference in the UK's cell and gene therapy companies. Furthermore, the UK is home to numerous prosperous businesses, top-notch academic institutions, and CGT Catapult, which is well-positioned to support market growth.
The Germany cell and gene therapy bioanalytical testing services market is expected to grow over the forecast period. The country's increased requirement for improved product designs, consulting, product maintenance, and related services is expected to be a crucial factor driving market growth in the coming years. Advancements in technology and the quality of clinical resources are some of the primary factors expected to propel this market over the forecast period. In addition, government initiatives for clinical research activities have accelerated the growth of the cell & gene therapy bioanalytical testing services market.
The cell and gene therapy bioanalytical testing services market in France is anticipated to witness significant growth over the forecast period. In France, the French Society for Cell and Gene Therapy is a nonprofit organization representing the demands of scientists working on developing innovative cell and gene therapies. Besides, a growing demand for biologics, such as gene therapies, cell-based therapies, and monoclonal antibodies, is expected to drive market growth.
Asia Pacific Cell And Gene Therapy Bioanalytical Testing Services Market Trends
The Asia Pacific market for cell and gene therapy bioanalytical testing services is expected to grow the fastest during the forecast period because of increased pharmaceutical and biotechnology activities, rising healthcare costs, more investments from major global companies to enhance local healthcare, and changes in regulations that align clinical trial evaluation with international standards. Furthermore, conducting clinical trials in countries like India is less expensive than in Western countries. This advantage has encouraged companies to relocate their production facilities to this region.
China's cell and gene therapy bioanalytical testing services market is expected to grow over the forecast period due to the country's active investments and advancements in cell and gene therapy capabilities. The country has a rapidly growing biotechnology & pharmaceutical sector, and it has shown significant interest and progress in this field. Gene therapies, such as Chimeric Antigen Receptor (CAR) T-cell immunotherapy, have been reported to be effective treatments for diseases such as cancer and HIV infection. China is home to the third-highest number of gene therapy clinical trials worldwide. China's rapidly evolving healthcare landscape and patient needs played a significant role in driving the cell & gene therapy bioanalytical testing services market.
The cell and gene therapy bioanalytical testing services market in Japan is expected to grow over the forecast period due to the rising demand for biopharmaceutical drugs to diagnose and treat various chronic diseases. Japan is one of the world’s largest pharmaceutical markets, actively involved in improving access to biopharmaceutical drugs. Several key players have expanded their contract manufacturing offerings in Japan to increase their product capacity to produce highly potent pharmaceutical dosage forms.
The Indiacell and gene therapy bioanalytical testing services market is emerging as one of the lucrative markets for bioanalytical testing worldwide. Low costs, the availability of industry experts, and the presence of WHO-cGMP-compliant facilities contribute to this. Furthermore, we expect the country's relatively high burden of genetic disorders to increase the demand for diagnostic tests. Therefore, we anticipate significant growth in the market for cell and gene therapy bioanalytical testing services in India.
Latin America Cell And Gene Therapy Bioanalytical Testing Service Market Trends
The increasing demand for pharmaceutical drugs is fueling the Latin America cell and gene therapy bioanalytical testing services market as pharmaceutical companies are investing in R&D. Furthermore, the presence of research training institutes in the region, the growing number of clinical trials, and the rising burden of diseases drive expansion in the Latin America market.
The cell and gene therapy bioanalytical testing services market in Brazil is expected to grow over the forecast period, as Brazil is currently the first Latin American country to authorize gene therapy product marketing. Moreover, bioanalytical testing services for cell and gene therapy are growing in the country due to the strong growth and innovation in the biologics industry and the expanding biopharmaceutical market.
Key Cell And Gene Therapy Bioanalytical Testing Services Company Insights
Key players operating in the market include BioAgilytix Labs, KCAS Bioanalytical Services, Inc., Laboratory Corporation of America Holdings, Pharmaceutical Product Development, Inc. (Thermo Fisher Scientific Inc.), and Prolytix. The major players operating across the cell & gene therapy bioanalytical testing services market are focused on the adoption of inorganic strategic initiatives such as mergers, partnerships, acquisitions, etc. For instance, in January 2024, Pharmaceutical Product Development, Inc. (Thermo Fisher Scientific, Inc.) launched the Gibco Cell Therapy Systems Cellmation Software to automate workflows for manufacturing cell therapies.
Key Cell And Gene Therapy Bioanalytical Testing Services Companies
The following are the leading companies in the cell and gene therapy bioanalytical testing services market. These companies collectively hold the largest market share and dictate industry trends.
- BioAgilytix Labs
- KCAS Bioanalytical Services
- IQVIA, Inc.
- Laboratory Corporation of America Holdings
- Pharmaceutical Product Development, Inc. (Thermo Fisher Scientific Inc.)
- Prolytix
- Pharmaron
- Charles River Laboratories
- Syneos Health
- SGS SA
- Intertek Group Plc
Recent Developments
-
In March 2024, Allumiqs and Prolytix entered into a strategic partnership aimed at offering integrated solutions to streamline drug development pipelines. By bringing together knowledge in multiomics and LC-MS/MS solutions with managing the lifecycle of large-molecule drugs, the partnership aimed to give customers simpler solutions, making the research and development process less complicated and risky.
-
In February 2024, Thermo Fisher Scientific’s PPD clinical research division expanded its GMP lab in Middleton, Wisconsin, to offer mycoplasma and biosafety testing services, aiding biopharmaceutical companies in ensuring product purity and patient safety. These new capabilities addressed the growing global demand for pathogen testing, particularly the rise of chronic diseases, and utilized advanced nucleic acid analysis techniques for faster and more accurate results.
-
In January 2024, Pharmaceutical Product Development, Inc. (Thermo Fisher Scientific, Inc.) launched the Gibco Cell Therapy Systems Cellmation Software to automate workflows for manufacturing cell therapies.
Cell And Gene Therapy Bioanalytical Testing Services Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 579.9 million |
|
Revenue forecast in 2030 |
USD 828.7 million |
|
Growth Rate |
CAGR of 7.40% from 2025 to 2030 |
|
Historical Year |
2018-2024 |
|
Forecast period |
2025-2030 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Test type, product type, stage of development by product type, indication, region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Country scope |
U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; India; Japan; Australia; Thailand; South Korea; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
|
Key companies profiled |
BioAgilytix Labs; KCAS Bioanalytical Services; IQVIA, Inc.; Laboratory Corporation of America Holdings; Pharmaceutical Product Development, Inc. (Thermo Fisher Scientific Inc.); Prolytix; Pharmaron; Charles River Laboratories; Syneos Health; SGS SA; Intertek Group Plc |
|
Customization scope |
Free report customization (equivalent to up to 8 analysts' working days) with purchase. Changes or additions to the scope of the country, region, and segment are possible. |
|
Pricing and purchase options |
Avail yourself of customized purchase options to meet your exact research needs. Explore purchase options |
Global Cell And Gene Therapy Bioanalytical Testing Services Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of industry trends in each of the subsegments from 2018 to 2030. For the purpose of this study, MIR has segmented the global cell and gene therapy bioanalytical testing services market on the basis of test type, product type, stage of development by product type, indication, and region
-
Test Type Outlook (Revenue, USD Million, 2018-2030)
-
Bioavailability & Bioequivalence Studies
-
Pharmacokinetics
-
Pharmacodynamics
-
Other Test Type
-
-
Product Type Outlook (Revenue, USD Million, 2018-2030)
-
Gene Therapy
-
Ex-vivo
-
In-vivo
-
-
Gene-Modified Cell Therapy
-
CAR T-cell therapies
-
CAR-NK cell therapy
-
TCR-T cell therapy
-
Other
-
-
Cell Therapy
-
-
Stage of Development by Product Type Outlook (Revenue, USD Million, 2018-2030)
-
Non-Clinical
-
Gene Therapy
-
Gene-Modified Cell Therapy
-
Cell Therapy
-
-
Clinical
-
Gene Therapy
-
Gene-Modified Cell Therapy
-
Cell Therapy
-
-
-
Indication Outlook (Revenue, USD Million, 2018 - 2030)
-
Oncology
-
Infectious Diseases
-
Neurological disorders
-
Rare Diseases
-
Others
-
-
Regional Outlook (Revenue, USD Million, 2018 - 2030)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
South Korea
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy